



IPW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/747855-Conf. #2748
	Filing Date	December 29, 2003
	First Named Inventor	Leonid A. Kozhemyakin
	Art Unit	1654
	Examiner Name	J. E. Russel
Total Number of Pages in This Submission	Attorney Docket Number	P0633.70014US01

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Receipt Postcard
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	WOLF, GREENFIELD & SACKS, P.C.		
Signature			
Printed name	Timothy J. Oyer, Ph.D.		
Date	5/24/04	Reg. No.	36,628

Certificate of Mailing Under 37 CFR 1.8(a)	
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
Dated: 5/24/04	Signature: (Angela M. Griffith)



DOCKET NO.: P0633.70014US01


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kozhemyakin, et al.
Serial No.: 10/747,855
Confirmation No.: 2748
Filed: December 29, 2003
For: METHODS FOR PRODUCTION OF OXIDIZED
GLUTATHIONE COMPOSITE WITH CIS-
DIAMMINEDICHLOROPLATINUM AND
PHARMACEUTICAL COMPOSITIONS BASED
THEREOF REGULATING METABOLISM,
PROLIFERATION, DIFFERENTIATION AND
APOPTOTIC MECHANISMS FOR NORMAL AND
TRANSFORMED CELLS

Examiner: Jeffrey E. Russel
Art Unit: 1654

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 20th day of May, 2006.


Angela M. Griffith

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 C.F.R. §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicants request consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114.

No fee or certification is required.

PART II: Information Cited

The Applicants hereby make of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicants make no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicants make no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.


Serial No.: 10/747,855
Conf. No.: 2748

- 3 -

Art Unit: 1654

Respectfully submitted,

By:



Timothy J. Oyer, Ph.D., Reg. No. 36,628
Tani Chen, Sc.D., Reg No. 52,728
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: P0633.70014US01
Date: May 24, 2006
xNDDx



FORM PTO-449/A and B (Modified PTO/SB/08)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICATION NO.: 10/747,855 ATTY. DOCKET NO.: P0633.70014US01

FILING DATE: December 29, 2003 CONFIRMATION NO.: 2748

APPLICANT: Kozhemyakin, et al.

GROUP ART UNIT: 1654 EXAMINER: Jeffrey E. Russel

Sheet 1 of 6

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
		5,206,220		Hilton	04/27/1993
		5,208,249		Rowe, et al.	05/04/1993

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
		JP	10-59839				(abstract)
		JP	62-221698				(abstract)
		JP	4-9336				(abstract)

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		Ahmed, K.A., et al., "Nonenzymic Reactivation of Reduced Bovine Pancreatic Ribonuclease by Air Oxidation and by Glutathione Oxidoreduction Buffers," <i>The Journal of Biological Chemistry</i> , Vol. 250, No. 21, pp. 8477-8482 (1975).	
		Araie, M., et al., "Effect of Oxidized Glutathione on the Barrier Function of the Corneal Endothelium," <i>Investigative Ophthalmology & Visual Science</i> , Vol. 29, pp. 1884-1887 (1988)	
		Aukrust, P., et al., "Increased Levels of Oxidized Glutathione in CD4 ⁺ Lymphocytes Associated With Disturbed Intracellular Redox Balance in Human Immunodeficiency Virus Type 1 Infection," <i>Blood</i> , Vol. 86, No. 1, pp. 258-267 (1995).	
		Barbato, G., et al., "Inhibitor binding induces active site stabilization of the HCV NS3 protein serine protease domain," <i>The EMBO Journal</i> , Vol. 19, No. 6, pp. 1195-1206 (2000).	
		Barot-Ciorbaru, R., et al., "Immunomodulators from <i>Nocardia opaca</i> ," <i>Forum on immunomodulators</i> , pp. 63-77 (1995).	
		Beckett, G. J., et al., "Glutathione S-Transferases: Biomedical Applications," <i>Advances in Clinical Chemistry</i> , Vol. 30, pp. 281-381 (1993).	
		Beutler, E., "Nutritional and Metabolic Aspects of Glutathione," <i>Annu. Rev. Nutr.</i> , Vol. 9, pp. 287-302 (1989).	
		Blight, K.J., et al., "Molecular virology of hepatitis C virus: an update with respect to potential antiviral targets," <i>Antiviral Therapy</i> , Vol. 3, pp. 71-81 (1998).	
		Bloy, C., et al., "RU 41740 (Biostim), an immunomodulating agent from bacterial origin," <i>Forum on immunomodulators</i> , pp. 85-100 (1995).	
		Bouffard, P., et al., "An <i>in Vitro</i> Assay for Hepatitis C Virus NS3 Serine Proteinase," <i>Virology</i> , Vol. 209, pp. 52-59 (1995).	
		Butkiewicz, N, et al., "Virus-Specific Cofactor Requirement and Chimeric Hepatitis C Virus/GB Virus B Nonstructural Protein 3," <i>Journal of Virology</i> , Vol. 74, No. 9, pp. 4291-4301 (2000).	
		Butkiewicz, N. J., et al., "Hepatitis C NS3 Protease: Restoration of NS4A Cofactor Activity by N-Biotinylation of Mutated NS4A Using Synthetic Peptides," <i>Biochemical and Biophysical Research Communications</i> , Vol. 267, pp. 278-282 (2000).	



FORM PTO 1449/A and B (modified PTO/SB/08)


INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICATION NO.: 10/747,855	ATTY. DOCKET NO.: P0633.70014US01
FILING DATE: December 29, 2003	CONFIRMATION NO.: 2748
APPLICANT: Kozhemyakin, et al.	
GROUP ART UNIT: 1654	EXAMINER: Jeffrey E. Russel

Sheet 2 of 6

OTHER ART — NON PATENT LITERATURE DOCUMENTS

	Calabrese, F., et al., "Liver cell Apoptosis in Chronic Hepatitis C Correlates With Historical But Not Biochemical Activity or Serum HCV-RNA Levels," <i>Hepatology</i> , Vol. 31, No. 5, pp. 1153-1159 (2000).	
	Carreno, V., et al., "A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B*," <i>Journal of Hepatology</i> , Vol. 32, pp. 317-324 (2000).	
	Cerretani, M., et al., "A High-Throughput Radiometric Assay for Hepatitis C Virus NS3 Protease," <i>Analytical Biochemistry</i> , Vol. 266, pp. 192-197 (1999).	
	Chen, M., et al., "Human Murine Antibody Recognition is Focused on the ATPase/Helicase, But Not the Protease Domain of the Hepatitis C Virus Nonstructural 3 Protein," <i>Hepatology</i> , Vol. 28, pp. 219-224 (1998).	
	Cirelli, R., et al., "Interferons in human papillomavirus infections," <i>Antiviral Research</i> , Vol. 24, pp. 191-204 (1994).	
	Cohen, G., "Enzymatic/Nonenzymatic Sources of Oxyradicals and Regulation of Antioxidant Defenses," <i>Annals New York Academy of Sciences</i> , pp. 8-14.	
	De Flora, S., et al., "Antioxidant Activity and Other Mechanisms of Thiols Involved in Chemoprevention of Mutation and Cancer," <i>The American Journal of Medicine</i> , Vol. 91, pp. 122-130 (1991).	
	Devlin, et al., "Glutathione, Amino Acid Metabolism II: Metabolism of the Individual Amino Acids," <i>Textbook of Biochemistry with Clinical Correlations</i> , 3 rd Edition, pp. 522-528 (1992).	
	Dienstag, J. L., et al., "Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States," <i>The New England Journal of Medicine</i> , Vol. 341, No. 17, pp. 1256-1263 (1999).	
	Dillman, R. O., "The Clinical Experience with Interleukin-2 in Cancer Therapy," <i>Cancer Biotherapy</i> , Vol. 9, No. 3, pp. 183-209 (1994).	
	Droge, W., et al., "Functions of glutathione and glutathione disulfide in immunology and immunopathology," <i>The FASEB Journal</i> , Vol. 8, pp. 1132-1138 (1994).	
	Estrela, J.M., et al., "Regulation of glutathione metabolism in Ehrlich ascites tumour cells," <i>Biochem. J.</i> , Vol. 286, pp. 257-262 (1992).	
	Fabris, P., et al., "TTV infection in patients with acute hepatitis of defined aetiology and in acute non-A-E hepatitis," <i>Journal of Hepatology</i> , Vol. 32, pp. 661-665 (2000).	
	Fan, X.G., et al., "Circulating Th1 and Th2 cytokines in patients with hepatitis C virus infection," <i>Mediators of Inflammation</i> , Vol. 7, pp. 295-297 (1998).	
	Forman, A., "Neurologic Complications of Cytokine Therapy," <i>Oncology</i> , Vol. 8, No. 4, pp. 105-117 (1994).	
	Gallinari, P., et al., "Multiple Enzymatic Activities Associated with Recombinant NS3 Protein of Hepatitis C Virus," <i>J. Virol.</i> , Vol. 72, No. 8, pp. 6758-6769 (1998).	
	Galter, D., et al., "Distinct effects of glutathione disulphide on the nuclear transcription factors κ B and the activator protein-1," <i>Eur. J. Biochem.</i> , Vol. 221, pp. 639-348 (1994).	
	Garaci, E., et al., "Combination therapy with BRMs in cancer and infectious diseases," <i>Mechanisms of Ageing and Development</i> , Vol. 96, pp. 103-116 (1997).	
	Gillan, E., et al., "Colony-Stimulating Factors in the Modulation of Sepsis," <i>New Horizons</i> , Vol. 1, No. 1, pp. 96-109 (1993)	
	Gillis, D., et al., "Active versus passive immunization against hepatitis A in the Israel defence forces: a cost-benefit analysis," <i>Vaccine</i> , Vol. 18, pp. 3005-3010 (2000).	
	Giugliano, D., et. al., "Diabetes Mellitus, Hypertension, and Cardiovascular Disease: Which Role for Oxidative Stress?," <i>Metabolism</i> , Vol. 44, No. 3, pp. 363-368 (1995).	
	"Glutathione," <i>Unknown Dictionary (Russian) and translation</i> , p. 979.	
	Gregory, C.D., "Apoptosis: a role in neoplasia?," <i>Cell Proliferation</i> , Ch. 13, pp. 342.	



FORM PTO-1449/A and B (modified PTO/SB/08)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICATION NO.: 10/747,855

ATTY. DOCKET NO.: P0633.70014US01

FILING DATE: December 29, 2003

CONFIRMATION NO.: 2748

APPLICANT: Kozhemyakin, et al.

GROUP ART UNIT: 1654

EXAMINER: Jeffrey E. Russel

Sheet

3

of

6

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Gruner, N.H., et al., "Association of Hepatitis C Virus-Specific CD8+ T Cells with Viral Clearance in Acute Hepatitis C," *The Journal of Infectious Diseases*, Vol. 181, pp. 1528-1536 (2000).

Gwack, Y., et al., "Characterization of RNA Binding Activity and RNA Helicase Activity of the Hepatitis C Virus NS3 Protein," *Biochemical and Biophysical Research Communications*, Vol. 225, pp. 654-659 (1996).

Hack, C.E., et al., "C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2," *Intensive Care Med.*, Vol. 19, pp. S19-S28 (1993).

Hansson, M., et al., "The Colony Stimulating Factors," *Med. Oncol. & Tumor Pharmacother*, Vol. 10, No. 1/2, pp. 5-12 (1993).

Hargrove, M.E., "Regulation by Glutathione of the Activation and Differentiation of IL-4-Dependent Activated Killer Cells," *Cellular Immunology*, Vol. 149, pp. 433-443 (1993).

Hayashi, J., et al., "A Relationship between the Evolution of Hepatitis C and Variants, Liver Damage, and Hepatocellular Carcinoma in Patients with Hepatitis C Viremia," *The Journal of Infectious Diseases*, Vol. 181, pp. 1523-1527 (2000).

Hieber, U., et al., "Tumor Necrosis Factor for the Treatment of Malignancies," *Oncology*, Vol. 51, pp. 142-153 (1994).

Hockenbery, D.M., "Bcl-2 Functions in an Antioxidant Pathway to Prevent Apoptosis," *Cell*, Vol. 75, pp. 241-251 (1993).

Holmlund, J. T., "Cytokines," *Cancer Chemotherapy and Biological Response Modifiers Annual*, Vol. 14, pp. 150-206 (1993).

Hope, D. B., et al., "A Highly Potent Analogue of Oxytocin, Desamino-oxytocin," *The Journal of Biological Chemistry*, Vol. 237, No. 5, pp. 1563-1566 (1962).

Hou-Jun, Y., et al., "N-S phosphoryl migration in phosphoryl glutathion," *Int. J. Peptide Res.*, Vol. 42, pp. 39-43 (1993).

Hultgren, C., et al., "The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses," *Journal of General Virology*, Vol. 79, pp. 2381-2391 (1998).

Jones, R.J., et al., "Undetectable serum caeruloplasmin in a woman with chronic hepatitis C infection," *J. Hepatol*, Vol. 4, pp. 703-704 (2000).

Kamber, B., et al., "The Synthesis of Cystine Peptides by Iodine Oxidation of S-Trityl-cysteine and S-Acetamidomethyl-cystein Peptides," *Helvetica Chimica Acta*, Vol. 63, pp. 899-915 (1980).

Kato, E., et al., "Conversion of Thiols into Disulfides with Diethyl Bromomalonate," *Chem. Pharm. Bull.*, Vol. 34, pp. 486-495 (1986).

Kehrer, J. P., et al., "Cellular Reducing Equivalents and Oxidative Stress," *Free Radical Biology & Medicine*, Vol. 17, No. 1, pp. 65-75 (1994).


Keusch, G. T., "Antioxidants in Infection," *J. Nutr. Sci. Vitaminol.*, Vol. 39, pp. S23-S33 (1993).

Knodell Histological Activity Index (web page) last accessed 3/6/01

Kozhemyakin, L.A., et al., "Glutoxim, a disulfide-containing hexapeptide, ensures a favorable survival outcome and better tolerability of chemotherapy in patients with Stage III-IV non-small-cell lung cancer," *Novelos Power Point Presentation*, 4th Annual International Lung Cancer Conference, Greece, 4/27/01

Krieter, H., et al., "Infusion of Oxidized Glutathione Enhances Postischemic segment-shortening in dog hearts," *Cardioscience*, Vol. 5, No. 2, pp. 115-126 (1994).

Kyono, K., et al., "Detection of Hepatitis C Virus Helicase Activity Using the Scintillation Proximity Assay System," *Analytical Biochemistry*, Vol. 257, pp. 120-126 (1998).



FORM PTO-1449/A, and B (modified PTO/SB/08)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICATION NO.: 10/747,855

ATTY. DOCKET NO.: P0633.70014US01

FILING DATE: December 29, 2003

CONFIRMATION NO.: 2748

APPLICANT: Kozhemyakin, et al.

GROUP ART UNIT: 1654

EXAMINER: Jeffrey E. Russel

Sheet

4

of

6

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Lau, D., et al., "Hepatitis G Virus and Human Immunodeficiency Virus Coinfection: Response to Interferon- α Therapy," *The Journal of Infectious Diseases*, Vol. 180, pp. 1334-1337 (1999).

Lee, J.H., et al., "Antiviral Effect of Human Recombinant Interleukin-12 in Patients Infected with Hepatitis C Virus," *Journal of Medical Virology*, Vol. 60, pp. 264-268 (2000).

Li, C., et al., "Complete Regression of Well-established Tumors Using a Novel Water-Soluble Poly(L-Glutamic Acid)-Paclitaxel Conjugate," *Cancer Research*, Vol. 58, pp. 2404-2409 (1998).

Lyttle, M.H., et al., "Isozyme-Specific Glutathione-S-Transferase Inhibitors: Design and Synthesis," *J. of Medicinal Chemistry*, Vol. 37, pp. 189-194 (1994).

Lyttle, M.H., et al., "Glutathione-S-transferase Activates Novel Alkylating Agents," *J. Med. Chem.*, Vol. 37, pp. 1501-1507 (1994).

Malik, A.H., et al., "Chronic Hepatitis B Virus Infection: Treatment Strategies for the Next Millennium," *Annals of Internal Medicine*, Vol. 132, No. 9 (2000).

Malnick, S.D., et al., "Treatment of Chronic Hepatitis C Virus Infection," *The Annals of Pharmacotherapy*, Vol. 34, pp. 1156-1164 (2000).

McHutchinson, J.G., et al., "A Pilot Study of Daily Subcutaneous Interleukin-10 in Patients with Chronic Hepatitis C Infection," *Journal of Interferon and Cytokine Research*, Vol. 19, 1265-1270 (1999).

Meister, A., et al., "Glutathione," *Ann. Rev. Biochem.*, Vol. 52, pp. 711-760 (1983).

Meyer, M. et al., "H₂O₂ and antioxidants have opposite effects on activation of NF- κ B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor," *The EMBO Journal*, Vol. 12, No. 5, pp. 2005-2015 (1993).

Michiels, C., et al., "Importance of SE-Glutathione Peroxidase, Catalase, and CU/ZN-SOD for Cell Survival Against Oxidative Stress," *Free Radical Biology & Medicine*, Vol. 17, No. 3, pp. 235-248 (1994).

Missale, G., et al., "Mediatori citochinici nell'inflammatione acuta e nei fenomeni di cronicizzazione delle epatiti virali," *Ann. Ital. Med. Int.*, Vol. 10, pp. 14-18 (1995). (abstract)

Mittelman, M., et al., "Clinical Application of Recombinant Erythropoietin in Myelodysplasia," *Hematology/Oncology Clinics of North America*, Vol. 8, No. 5, pp. 993-1009 (1994).

Morstyn, G., et al., "Hematopoietic growth factors in cancer chemotherapy," *Cancer Chemotherapy and Biological Response Modifiers Annual*, Vol. 14, pp. 353-370 (1993).

Murray, H. W., "Interferon-Gamma and Host Antimicrobial Defense: Current and Future Clinical Applications," *The American Journal of Medicine*, Vol. 97, pp. 459-467 (1994).

Neidhart, J. A., "Hematopoietic Cytokines," *Cancer*, Vol. 72, No. 11, pp. 3381-3386 (1993).

Nelson, D.R., et al., "Interleukin 10 Treatment Reduces Fibrosis in Patients with Chronic Hepatitis C: A Pilot Trial of Interferon Nonresponders," *Gastroenterology*, Vol. 118, pp. 655-660 (2000).

Nelson, S., "Role of Granulocyte Colony-Stimulating Factor in the Immune Response to Acute Bacterial Infection in the Nonneutropenic Host: An Overview," *Clinical Infectious Diseases*, Vol. 18, pp. 197-204 (1994).

Nemunaitis, J., "User of hematopoietic growth factors in marrow transplantation," *Current Opinion in Oncology*, Vol. 6, pp. 139-145 (1994).

Nishida, T., et al., "The Network Structure of Corneal Fibroblasts in the Rat as Revealed by Scanning Electron Microscopy," *Investigative Ophthalmology & Visual Science*, Vol. 29, pp. 1887-1890 (1988).

Offenstadt, G., et al., "Cytokines et etats infectieux graves," *Path Biol.*, Vol. 41, pp. 820-831 (1993).

Pol, S., et al., "Combination of Ribavirin and Interferon-Alfa Surpasses High Doses of Interferon-Alfa Alone in Patients with Genotype-1b-Related Chronic Hepatitis C," *Hepatology*, Vol. 31, No. 6, pp. 1338-1344 (2000).



FORM PTO-1449 (APP) and B (modified PTO/SB/08)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICATION NO.: 10/747,855	ATTY. DOCKET NO.: P0633.70014US01
FILING DATE: December 29, 2003	CONFIRMATION NO.: 2748
APPLICANT: Kozhemyakin, et al.	
GROUP ART UNIT: 1654	EXAMINER: Jeffrey E. Russel

Sheet 5 of 6

OTHER ART — NON PATENT LITERATURE DOCUMENTS

	Polyak, S.J., et al., "The molecular basis for responsiveness to anti-viral therapy in hepatitis C," <i>Forum Trends in Experimental and Clinical Medicine</i> , No. 10.1, pp. 46-58 (2000).	
	Raggi, M.A., "Spectrophotometric determination of thiols in human lymphocytes," <i>Pharmazie</i> , Vol. 53, pp. 239-242 (1998).	
	Raggi, M.A., "Studio della cinetica di reazione tra Pd (II) e glutathione ossidato," <i>Bio. Chim. Parmaccurcio</i> , Vol. 131, No. 8, pp. 318-319 (1992).	
	Renard, D. C., et al., "Oxidized glutathione causes sensitization of calcium release to inositol 1,4,5-trisphosphate in permeabilized hepactocytes," <i>Biochem J.</i> , Vol. 284, pp. 507-512 (1992).	
	Rizzetto, M., et al., "Response of Pre-Core Mutant Chronic Hepatitis B Infection to Lamivudine," <i>Journal of Medical Virology</i> , Vol. 61, pp. 398-402 (2000).	
	Ryu, C. J., et al., "An 80-Kilodalton Protein That Binds to the Pre-S1 Domain of Hepatitis B Virus," <i>Journal of Virology</i> , Vol. 74, No. 1, pp. 110-116 (2000).	
	Saito, M., "OK-432, a killed streptococcal preparation, in the treatment of animal and human cancer and its mechanisms of action," <i>Forum on immunomodulators</i> , pp. 13-30.	
	Sardesai, V.M., "Role of Antioxidants in Health Maintenance," <i>Nutrition in Clinical Practice</i> , Vol. 10, pp. 19-25 (1995).	
	Schiff, E.R., "Lamivudine for Hepatitis B in Clinical Practice," <i>Journal of Medical Virology</i> , Vol. 61, pp. 386-391 (2000).	
	Sher, A., "Regulation of immunity to Parasites by T cells and T cell-derived cytokines," <i>Annu. Rev. Immunol.</i> , Vol. 10, pp. 385-409 (1992).	
	Sokolovsky, M., et al., "On the Synthesis of Cysteine Peptides," <i>J. Am. Chem. Soc.</i> , Vol. 86, pp. 1202-1206 (1963).	
	Suthanthiran, M., et al., "Glutathione regulates activation-dependent DNA synthesis in highly purified normal human T lymphocytes stimulated via the CD2 and CD3 antigens," <i>Proc. Natl. Acad. Sci.</i> , Vol. 87, pp. 3343-3347 (1990).	
	Staal, F., et al., "Intracellular thiols regulate activation of nuclear factor kb and transcription of human immunodeficiency virus," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 87, pp. 9943-9947 (199).	
	Szent-Gyorgyi, A., "Charge Transfer and Electronic Mobility," <i>Biochemistry</i> , Vol. 58, pp. 2012-2014 (1967).	
	Takikawa, S., et al., "Cell Fusion Activity of Hepatitis C Virus Envelope Proteins," <i>Journal of Virology</i> , Vol. 74, No. 11, pp. 5066-5074 (2000).	
	Tam, J. P., "Synthesis of biologically active transforming growth factor alpha," <i>Int. J. Peptide Protein Res.</i> , Vol. 29, pp. 421-432 (1987).	
	Terradez, P., et al., "Depletion of tumour glutathione <i>in vivo</i> by buthionine sulfoximine: modulation by the rate of cellular proliferation and inhibition of cancer growth," <i>Biochem. J.</i> , Vol. 292, pp. 447-483 (1993).	
	Tew, K. D., "Glutathione-associated Enzymes in Anticancer Drug Resistance," <i>Cancer Research</i> , Vol. 54, pp. 4313-4320 (1994).	
	Thomas, D. L., et al., "Determinants of the Quantity of Hepatitis C Virus RNA," <i>The Journal of Infectious Diseases</i> , Vol. 181, pp. 844-851 (2000).	
	Toyoda, H., et al., "Comparison of Characteristics Between Patients with GB Virus C/Hepatitis G Virus (GBV-C/HGV) RNA and those with GBV-C/HGV E2-Antibody in Patients with Hemophilia," <i>Journal of Medical Virology</i> , Vol. 60, pp. 34-38 (2000).	
	Trankmann, P., et al., "Einfluß der Substitution von Selen und Vitamin E auf Herzinsuffizienz und ventrikuläre Herzrhythmusstörungen bei Patienten mit akutem Myokardinfarkt," <i>Medizinische Klinik</i> , Vol. 94, Suppl. III, pp. 78-80 (1999).	



FORM PTO 1449/A and B (modified PTO/SB/08)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

APPLICATION NO.: 10/747,855

ATTY. DOCKET NO.: P0633.70014US01

FILING DATE: December 29, 2003

CONFIRMATION NO.: 2748

APPLICANT: Kozhemyakin, et al.

GROUP ART UNIT: 1654

EXAMINER: Jeffrey E. Russel

Sheet

6

of

6

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Westendorp, M. O., et al., "HIV-1 Tat potentiates TNF-induced NF-kB activation and cytotoxicity by altering the cellular redox state," *The EMBO Journal*, Vol. 14, No. 3, pp. 546-554 (1995).

Whittington, R., et al., "Interleukin-2; A Review of its Pharmacological Properties and Therapeutic Use in Patients with Cancer," *Drugs*, Vol. 46, No. 3, pp. 446-514 (1993).

Yang, S.H., et al., "Internal Cleavage of Hepatitis C Virus NS3 Protein is Dependent on the Activity of NS34A Protease," *Virology*, Vol. 268, pp. 132-140 (2000).

Yao, N., et al., "Helicase, a target for novel inhibitors of hepatitis C virus," *Antiviral Therapy*, Vol. 3, pp. 93-97 (1998).

International Search Report dated 01/27/1997, PCT/RU96/00226.

International Search Report dated 05/27/1997, PCT/RU96/00340.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]